Your browser doesn't support javascript.
loading
Proteolysis-targeting chimeras with reduced off-targets.
Nguyen, Tuan M; Sreekanth, Vedagopuram; Deb, Arghya; Kokkonda, Praveen; Tiwari, Praveen K; Donovan, Katherine A; Shoba, Veronika; Chaudhary, Santosh K; Mercer, Jaron A M; Lai, Sophia; Sadagopan, Ananthan; Jan, Max; Fischer, Eric S; Liu, David R; Ebert, Benjamin L; Choudhary, Amit.
Afiliación
  • Nguyen TM; Chemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Sreekanth V; Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • Deb A; Divisions of Renal Medicine and Engineering, Brigham and Women's Hospital, Boston, MA, USA.
  • Kokkonda P; Chemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Tiwari PK; Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • Donovan KA; Divisions of Renal Medicine and Engineering, Brigham and Women's Hospital, Boston, MA, USA.
  • Shoba V; Chemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Chaudhary SK; Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • Mercer JAM; Chemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Lai S; Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • Sadagopan A; Chemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Jan M; Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • Fischer ES; Divisions of Renal Medicine and Engineering, Brigham and Women's Hospital, Boston, MA, USA.
  • Liu DR; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Ebert BL; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
  • Choudhary A; Chemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Nat Chem ; 16(2): 218-228, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38110475
ABSTRACT
Proteolysis-targeting chimeras (PROTACs) are molecules that induce proximity between target proteins and E3 ligases triggering target protein degradation. Pomalidomide, a widely used E3 ligase recruiter in PROTACs, can independently degrade other proteins, including zinc-finger (ZF) proteins, with vital roles in health and disease. This off-target degradation hampers the therapeutic applicability of pomalidomide-based PROTACs, requiring development of PROTAC design rules that minimize off-target degradation. Here we developed a high-throughput platform that interrogates off-target degradation and found that reported pomalidomide-based PROTACs induce degradation of several ZF proteins. We generated a library of pomalidomide analogues to understand how functionalizing different positions of the phthalimide ring, hydrogen bonding, and steric and hydrophobic effects impact ZF protein degradation. Modifications of appropriate size on the C5 position reduced off-target ZF degradation, which we validated through target engagement and proteomics studies. By applying these design principles, we developed anaplastic lymphoma kinase oncoprotein-targeting PROTACs with enhanced potency and minimal off-target degradation.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Talidomida / Proteínas / Ubiquitina-Proteína Ligasas Idioma: En Revista: Nat Chem Asunto de la revista: QUIMICA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Talidomida / Proteínas / Ubiquitina-Proteína Ligasas Idioma: En Revista: Nat Chem Asunto de la revista: QUIMICA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos